|
1
|
Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM
and Baek KH: The expression patterns of deubiquitinating enzymes,
USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang XY, Varthi M, Sykes SM, et al: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Y, Lang G, Ito S, et al: A TFTC/STAGA
module mediates histone H2A and H2B deubiquitination, coactivates
nuclear receptors, and counteracts heterochromatin silencing. Mol
Cell. 29:92–101. 2008. View Article : Google Scholar
|
|
4
|
Lin Z, Yang H, Kong Q, et al: USP22
antagonizes p53 transcriptional activation by deubiquitinating
Sirt1 to suppress cell apoptosis and is required for mouse
embryonic development. Mol Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Atanassov BS and Dent SY: USP22 regulates
cell proliferation by deubiquitinating the transcriptional
regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glinsky GV: Death-from-cancer signatures
and stem cell contribution to metastatic cancer. Cell Cycle.
4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kouzarides T: Acetylation: a regulatory
modification to rival phosphorylation? EMBO J. 19:1176–1179. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawai H, Li H, Avraham S, Jiang S and
Avraham HK: Overexpression of histone deacetylase HDAC1 modulates
breast cancer progression by negative regulation of estrogen
receptor alpha. Int J Cancer. 107:353–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan H, Heckman CA and Boxer LM: Histone
deacetylase inhibitors down-regulate bcl-2 expression and induce
apoptosis in t(14;18) lymphomas. Mol Cell Biol. 25:1608–1619. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu YF, Sheu JR, Lin CH, et al:
Trichostatin A and sirtinol suppressed survivin expression through
AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta.
1820:104–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han JW, Ahn SH, Kim YK, et al: Activation
of p21(WAF1/Cip1) transcription through Sp1 sites by histone
deacetylase inhibitor apicidin: involvement of protein kinase C. J
Biol Chem. 276:42084–42090. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiong J, Che X, Li X, Yu H, Gong Z and Li
W: Cloning and characterization of the human USP22 gene promoter.
PLoS One. 7:e527162012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakamoto S, Potla R and Larner AC: Histone
deacetylase activity is required to recruit RNA polymerase II to
the promoters of selected interferon-stimulated early response
genes. J Biol Chem. 279:40362–40367. 2004. View Article : Google Scholar
|
|
15
|
Zhang Y and Dufau ML: Silencing of
transcription of the human luteinizing hormone receptor gene by
histone deacetylase-mSin3A complex. J Biol Chem. 277:33431–33438.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong Y, Dowdy SC, Podratz KC, et al:
Histone deacetylase inhibitors decrease DNA methyltransferase-3B
messenger RNA stability and down-regulate de novo DNA
methyltransferase activity in human endometrial cells. Cancer Res.
65:2684–2689. 2005. View Article : Google Scholar
|
|
17
|
Chen WY, Weng JH, Huang CC and Chung BC:
Histone deacetylase inhibitors reduce steroidogenesis through
SCF-mediated ubiquitination and degradation of steroidogenic factor
1 (NR5A1). Mol Cell Biol. 27:7284–7290. 2007. View Article : Google Scholar
|
|
18
|
Ovaa H, Kessler BM, Rolen U, Galardy PJ,
Ploegh HL and Masucci MG: Activity-based ubiquitin-specific
protease (USP) profiling of virus-infected and malignant human
cells. Proc Natl Acad Sci USA. 101:2253–2258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Waby JS, Chirakkal H, Yu C, et al: Sp1
acetylation is associated with loss of DNA binding at promoters
associated with cell cycle arrest and cell death in a colon cell
line. Mol Cancer. 9:2752010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suzuki T, Kimura A, Nagai R and Horikoshi
M: Regulation of interaction of the acetyltransferase region of
p300 and the DNA-binding domain of Sp1 on and through DNA binding.
Genes Cells. 5:29–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Furumai R, Ito A, Ogawa K, et al: Histone
deacetylase inhibitors block nuclear factor-kappaB-dependent
transcription by interfering with RNA polymerase II recruitment.
Cancer Sci. 102:1081–1087. 2011. View Article : Google Scholar
|
|
22
|
Choi KH, Basma H, Singh J and Cheng PW:
Activation of CMV promoter-controlled glycosyltransferase and
beta-galactosidase glycogenes by butyrate, tricostatin A, and
5-aza-2′-deoxycytidine. Glycoconj J. 22:63–69. 2005.PubMed/NCBI
|
|
23
|
Armour SM, Bennett EJ, Braun CR, et al: A
high-confidence interaction map identifies SIRT1 as a mediator of
acetylation of USP22 and the SAGA coactivator complex. Mol Cell
Biol. 33:1487–1502. 2013. View Article : Google Scholar
|
